Darmiyan Darmiyan Receives FDA Approval for Post-Market Surveillance Study of BrainSee, the First-in-Class Clinical Test for Predicting Risk of Progression to Clinical Alzheimer’s Disease BioSpace 2025.05.29
Darmiyan Darmiyan Enters Medicare GUIDE Program Through Partnership with Five Star Home Health Care, CareBrains, and Brain Watch Coalition Bio Space 2024.12.19
Darmiyan Darmiyan, Inc. Announces Launch of Groundbreaking BrainSee Platform for Alzheimer’s Testing BioSpace 2024.09.16
Darmiyan Moving Ahead With Positive Health Lessons and Innovative Predictions (by Darmiyan) Medscape 2022.01.25
Darmiyan Darmiyan CEO speaks at What’s Next Longevity Innovation Summit – Available on-demand through Feb 28, 2022 What’s Next Longevity Innovation Summit 2021.12.01
Darmiyan The Top 25 Women Leaders in Biotechnology of 2021 The Healthcare Technology Report 2021.10.19
Darmiyan FDA: (Darmiyan’s) BrainSee Novel Software Is Breakthrough for Noninvasive Detection and Monitoring of Alzheimer’s Disease at the Early Stage of Mild Cognitive Impairment yahoo!finance 2021.05.29
Darmiyan ASNR Journal: (Darmiyan’s) BrainSee Enterprise Software Is Reliable, Accurate for Alzheimer’s Disease Detection Reportable 2021.05.24
Darmiyan The first Virtual Microscope of the human brain, developed by Darmiyan, accurately measures Alzheimer’s-related abnormalities PR Newswire 2020.08.11
Darmiyan Global Pharma Giant Eisai Leads a $6M Series Seed Investment Round in Darmiyan to Expedite its Clinical Market Entry PR Newswire 2020.04.10
